← Back to patent-cliff list
Maralixibat Chloride
Tier C — Watch / tradeMaralixibat Chloride
Pfizer Inc.
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IBAT
Brand：LIVMARLI
Indications (approved)：Pruritus, 进行性家族性肝内胆汁淤积症, Alagille综合征
Regional status
US
Approved
2021-09-29
EU
Approved
2022-12-09
China
Approved
2023-05-29
Japan
Phase III
2023-01-10
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Maralixibat Chloride?
Approved indications include: Pruritus, 进行性家族性肝内胆汁淤积症, Alagille综合征.
When does the Maralixibat Chloride patent expire?
No public expiry year is available for Maralixibat Chloride yet; this page updates once verified.
How do I get a quote for Maralixibat Chloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27